1. Changes in choroidal thickness quantified by Optical Coherence Tomography across cognitive impairment: data from the NORFACE cohort.
- Author
-
Castilla-Martí L, García-Sánchez A, Martínez J, Rosende-Roca M, Vargas L, Tartari JP, Casales F, Rodríguez JN, Bein N, Alegret M, Ortega G, Espinosa A, Sanabria Á, Pérez-Cordón A, Muñoz N, García-Gutiérrez F, Blazquez-Folch J, Miguel A, de Rojas I, García-González P, Puerta R, Olivé C, Capdevila M, Muñoz-Morales Á, Bayón-Buján P, Cano A, Fernández V, Valero S, Tárraga L, Ruiz A, Boada M, Castilla-Martí M, and Marquié M
- Subjects
- Humans, Male, Female, Aged, Cohort Studies, Middle Aged, Aged, 80 and over, Alzheimer Disease diagnostic imaging, Alzheimer Disease pathology, Cerebrovascular Disorders diagnostic imaging, Cerebrovascular Disorders pathology, Tomography, Optical Coherence methods, Cognitive Dysfunction diagnostic imaging, Cognitive Dysfunction pathology, Choroid diagnostic imaging, Choroid pathology
- Abstract
Background: Optical coherence tomography (OCT) enables high-resolution imaging of ocular structures in health and disease. Choroid thickness (CT) is a key vascular retinal parameter that can be assessed by OCT and might be relevant in the evaluation of the vascular component of cognitive decline. We aimed to investigate CT changes in a large cohort of individuals cognitive unimpaired (CU), with mild cognitive impairment due to Alzheimer's (MCI-AD), mild cognitive impairment due to cerebrovascular disease (MCI-Va), Alzheimer's disease dementia (ADD), and vascular dementia (VaD)., Methods: Clinical, demographical, ophthalmological and OCT data from the Neuro-ophthalmological Research at Fundació ACE (NORFACE) project were analyzed. CT was assessed in the macula across nine Early Treatment Diabetic Retinopathy Study (ETDRS) quadrants, average thickness, total volume, and subfoveal choroidal thickness. Differences of CT among the five diagnostic groups were assessed in a multivariate regression model, adjusting for demographic and cardiovascular risk factors and OCT image quality. A comparison between manual and automatic CT measurements in a subset of participants was also performed., Results: The study cohort comprised 1,280 participants: 301 CU, 196 MCI-AD, 112 MCI-Va, 578 ADD, and 93 VaD. CT was significantly increased in individuals with cognitive impairment compared to those CU, particularly in the VaD and MCI-Va groups and in the peripheral ETDRS regions. No significant differences were found in inner superior, center and subfoveal choroidal thickness. The interaction of sex and diagnosis had no effect in differentiating CT. Mini-Mental State Examination (MMSE) scores were not correlated to CT. Manual and automated CT measurements showed good reliability., Discussion: Our findings indicated that peripheral choroidal thickening, especially in patients with cerebrovascular disease, may serve as a potential choroidal biomarker for cognitive decline and suggest different pathogenic pathways in AD and VaD. Further research is required to explore CT as a reliable ocular biomarker for cognitive impairment., Competing Interests: Declarations Ethics approval and consent to participate This study and its informed consent were approved by the Ethics Committee of the Hospital Clínic i Provincial de Barcelona in accordance with Spanish biomedical laws (Law 14/2007, of July 3, on biomedical research; Royal Decree 1716/2011, of November 18) and followed the recommendations of the declaration of Helsinki. All participants signed an informed consent form (in the case of individuals with moderate stages of dementia, informed consent was signed by their legal representative or family member). Consent for publication Not applicable. Competing interests MB has consulted for Araclon, Avid, Grifols, Lilly, Nutricia, Roche, Eisai and Servier. She received fees from lectures and funds for research from Araclon, Biogen, Grifols, Nutricia, Roche and Servier. She reports grants/research funding from Abbvie, Araclon, Biogen Research Limited, Bioiberica, Grifols, Lilly, S.A, Merck Sharp & Dohme, Kyowa Hakko Kirin, Laboratorios Servier, Nutricia SRL, Oryzon Genomics, Piramal Imaging Limited, Roche Pharma SA, and Schwabe Farma Iberica SLU, all outside the submitted work. She has not received personal compensations from these organizations. AR is member of scientific advisory board of Landsteiner Genmed and Grifols SA. AR has stocks of Landsteiner Genmed. MM has consulted for F. Hoffmann-La Roche Ltd. The rest of authors declare that they have no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF